Last reviewed · How we verify
Carboplatin AUC-10
Alkylating agent that forms platinum-DNA adducts, inhibiting DNA replication and transcription.
Alkylating agent that forms platinum-DNA adducts, inhibiting DNA replication and transcription. Used for Ovarian cancer, Breast cancer, Lung cancer.
At a glance
| Generic name | Carboplatin AUC-10 |
|---|---|
| Sponsor | Barts & The London NHS Trust |
| Drug class | Platinum-based chemotherapy |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Carboplatin is a platinum-based chemotherapy drug that works by forming platinum-DNA adducts, which interfere with DNA replication and transcription, ultimately leading to cell death.
Approved indications
- Ovarian cancer
- Breast cancer
- Lung cancer
Common side effects
- Neutropenia
- Thrombocytopenia
- Anemia
Key clinical trials
- THERApy De-escalation for TESTicular Cancer
- Auto-HSCT-Supported Dose-Dense Chemotherapy with Adebrelimab As First-Line Treatment for ES-SCLC (PHASE1, PHASE2)
- Carboplatin AUC-10 With Early PET Scanning in Metastatic Seminoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Carboplatin AUC-10 CI brief — competitive landscape report
- Carboplatin AUC-10 updates RSS · CI watch RSS
- Barts & The London NHS Trust portfolio CI